
Insider and congress filings
Biogen Inc. (BIIB)
NASDAQ · Healthcare · 297 insider transactions · 126 congress trades · last filed 18 days agoS&P 500
About Biogen Inc.
from the company's filings and listing, as of Oct 22, 2026- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Chief executive
- Christopher A. Viehbacher
- Employees
- 7,500
- Listed since
- Sep 17, 1991
- Market value
- $35.6B
- Price to earnings (12 mo)
- 42.4
- Net income per share, as reported (12 mo)
- $5.65
- Dividend yield
- -
Company news
1 article · newest first| Headline | Source | Date |
|---|---|---|
| Biogen presents 52-week litifilimab data in cutaneous lupus erythematosusParticipants who switched from placebo to litifilimab at Week 24 showed a rapid onset of effect as early as four weeks. | Company release | Oct 2, 2026 |
Written by GetSignal with AI from the company's own SEC filings and press releases; each article links to its source. Not investment advice. Company news from every company we cover
Earnings
6 reported quarters · next on Oct 28, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Jul 29, 2026 | $3.60 | $2.94 | $2.7B | $2.5B | EPS beatRevenue beat |
| Q1 FY2026reported Apr 29, 2026 | $3.57 | $3.05 | $2.5B | $2.3B | EPS beatRevenue beat |
| Q4 FY2025reported Feb 6, 2026 | $1.99 | $1.63 | $2.3B | $2.2B | EPS beatRevenue beat |
| Q3 FY2025reported Oct 30, 2025 | $4.81 | $3.88 | $2.5B | $2.3B | EPS beatRevenue beat |
| Q2 FY2025reported Jul 31, 2025 | $5.47 | $3.90 | $2.6B | $2.3B | EPS beatRevenue beat |
| Q1 FY2025reported May 1, 2025 | $3.02 | $2.90 | $2.4B | $2.2B | EPS beatRevenue beat |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for fiscal 2025 · proxy filed Apr 28, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Christopher A. ViehbacherPresident and Chief Executive Officer | $1.7M | $18.4M | $3.5M | $23.6M |
| Susan H. AlexanderExecutive Vice President, Chief Legal Officer | $1.0M | $5.8M | $1.3M | $8.1M |
| Nicole C.Murphy Head of Pharmaceutical Operations and Technology | $909K | $5.6M | $1.1M | $7.6M |
| Priya A.Singhal Head of Development | $930K | $5.6M | $1.1M | $7.6M |
| Robin C. KramerExecutive Vice President and Chief Financial Officer | $760K | $4.2M | $873K | $5.8M |
The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. 1 executive who has since left the company is named in that filing and not shown here. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Shares vs prior qtr | % of shares out |
|---|---|---|---|---|
| FMR LLC | $3.9B | 18,217,239 | +42.2% | 12.33% |
| BlackRock, Inc. | $3.5B | 15,985,736 | +0.1% | 10.82% |
| Primecap Management Co | $3.3B | 15,154,606 | +2.7% | 10.26% |
| Vanguard Capital Management LLC | $2.1B | 9,651,117 | +1.2% | 6.53% |
| State Street Corp | $1.6B | 7,344,327 | +2.5% | 4.99% |
| Vanguard Portfolio Management LLC | $1.4B | 6,604,936 | +1.1% | 4.47% |
| Geode Capital Management, LLC | $957.9M | 4,449,295 | +2.5% | 3.01% |
| Wellington Management Group LLP | $673.6M | 3,117,469 | +5.3% | 2.11% |
| Norges Bank | $557.4M | 2,580,033 | New | 1.75% |
| Morgan Stanley | $521.0M | 2,411,271 | +11.1% | 1.63% |
| AQR Capital Management LLCCliff Asness | $416.9M | 1,936,859 | +0.7% | 1.31% |
| JPMorgan Chase & Co. | $394.9M | 1,823,140 | -9.6% | 1.23% |
A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. New: not in this holder's prior 13F as reported; a change of filer ID can also show as new. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.
Tracked fund managers holding BIIB
2 managers| Manager | Value | Shares | Share of book |
|---|---|---|---|
| Alyeska Investment Group | $201.4M | 932,374 | 0.5% |
| Perceptive AdvisorsJoseph Edelman | $59.7M | 276,173 | 0.9% |
2 of the 97 fund managers we track list BIIB shares among the largest positions in their latest 13F, filed for Q2 2026. A manager can hold it further down the book too, so this is a floor, not a count. Share of book is the position against the manager's whole disclosed 13F value.
Open-market insider trades
4 filings shown · newest filing first| Insider | Action | Shares | Price | Value | Trade date | Delay (business days) |
|---|---|---|---|---|---|---|
| Lloyd MinorDirector | Sold · scheduled | 593 | $200.96 | $119K | Aug 4, 2026filed Aug 5, 2026 | 1d |
| Lloyd MinorDirector | Sold · scheduled | 593 | $203.34 | $121K | Aug 3, 2026filed Aug 5, 2026 | 2d |
| Nicole MurphyHead of Pharm Ops and Tech | Bought | 3 | $195.03 | $585 | Feb 12, 2026filed Feb 17, 2026 | 2d |
| Priya SinghalHead of Development | Sold · scheduled | 2,660 | $199.83 | $532K | Feb 9, 2026filed Feb 10, 2026 | 1d |
One row is one filing, newest filing first. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count. Scheduled: set up in advance under a Rule 10b5-1 trading plan. The delay counts business days from the trade to the filing, the unit of Form 4's two business day deadline: weekends and federal holidays are skipped. How the filing itself works is explained in our guide to Form 4.
Other Form 4 activity (20)
| Insider | Event | Shares | Date |
|---|---|---|---|
| Sean GodboutChief Accounting Officer | Stock award | 985 | Oct 1, 2026 |
| Sean GodboutChief Accounting Officer | Tax withholding | 8 | Oct 2, 2026 |
| Sean GodboutChief Accounting Officer | Option exercise | 27 | Oct 2, 2026 |
| Michael PariniChief Legal Officer | Stock award | 7,405 | Sep 1, 2026 |
| Maria C. FreireDirector | Stock award | 2,005 | Jun 9, 2026 |
| Lloyd MinorDirector | Stock award | 1,505 | Jun 9, 2026 |
| Menelas N. PangalosDirector | Option exercise | 2,370 | Jun 9, 2026 |
| Menelas N. PangalosDirector | Stock award | 1,505 | Jun 9, 2026 |
| Monish D. PatolawalaDirector | Stock award | 1,505 | Jun 9, 2026 |
| Susan LangerDirector | Stock award | 1,505 | Jun 9, 2026 |
| Jesus B. MantasDirector | Stock award | 1,505 | Jun 9, 2026 |
| Eric K. RowinskyDirector | Stock award | 1,505 | Jun 9, 2026 |
| Stephen A. SherwinDirector | Stock award | 1,505 | Jun 9, 2026 |
| William A. HawkinsDirector | Stock award | 1,505 | Jun 9, 2026 |
| Adam KeeneyHead of Corporate Development | Tax withholding | 455 | May 1, 2026 |
| Adam KeeneyHead of Corporate Development | Option exercise | 939 | May 1, 2026 |
| Sean GodboutChief Accounting Officer | Tax withholding | 54 | Apr 1, 2026 |
| Sean GodboutChief Accounting Officer | Option exercise | 181 | Apr 1, 2026 |
| Susan H. AlexanderEVP Chief Legal Officer | Stock award | 8,450 | Feb 13, 2026 |
| Sean GodboutChief Accounting Officer | Stock award | 1,800 | Feb 13, 2026 |
Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.
Congress trades in BIIB
20 disclosures of 126 on record · median 26d of the 45 allowedSince the trade: the stock's move from the trade date to the latest close we hold (figures as of Oct 24, 2026), not the member's result. Not investment advice.
| Member | Type | Action | Amount disclosed | Stock since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Maria Elvira Salazar | Stock | Sale | $1,001 - $15,000 | +10.8%After the saleS&P 500 -1.2% · +11.9 pts vs S&P 500 | Sep 24, 2026 | Oct 7, 2026 | 13d |
| Kevin Hern | Stock | Sale | $1,001 - $15,000 | +17.9%After the saleS&P 500 -1.0% · +18.9 pts vs S&P 500 | Aug 18, 2026 | Sep 1, 2026 | 14d |
| Alan ArmstrongSelf | Stock | Purchase | $1,001 - $15,000 | +36.4%S&P 500 +19.8% · +16.5 pts vs S&P 500 | Mar 27, 2026 | Jul 21, 2026 | 116d |
| Maria Elvira Salazar | Stock | Sale | $15,001 - $50,000 | +32.8%After the saleS&P 500 +0.1% · +32.7 pts vs S&P 500 | Jun 2, 2026 | Jul 7, 2026 | 35d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | +28.3%S&P 500 +3.0% · +25.3 pts vs S&P 500 | Jun 5, 2026 | Jul 2, 2026 | 27d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +29.9%S&P 500 +2.8% · +27.1 pts vs S&P 500 | May 15, 2026 | Jun 9, 2026 | 25d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +27.3%After the saleS&P 500 +1.3% · +26.0 pts vs S&P 500 | May 27, 2026 | Jun 9, 2026 | 13d |
| Maria Elvira Salazar | Stock | Purchase | $50,001 - $100,000 | +26.6%S&P 500 +2.8% · +23.8 pts vs S&P 500 | May 11, 2026 | Jun 8, 2026 | 28d |
| Maria Elvira Salazar | Stock | Purchase | $1,001 - $15,000 | +26.6%S&P 500 +2.8% · +23.8 pts vs S&P 500 | May 11, 2026 | Jun 8, 2026 | 28d |
| Maria Elvira Salazar | Stock | Purchase | $1,001 - $15,000 | +25.8%S&P 500 +2.9% · +22.8 pts vs S&P 500 | May 12, 2026 | Jun 8, 2026 | 27d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +42.1%After the saleS&P 500 +10.8% · +31.4 pts vs S&P 500 | Apr 13, 2026 | May 11, 2026 | 28d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +24.6%After the saleS&P 500 +10.0% · +14.6 pts vs S&P 500 | Feb 6, 2026 | Mar 9, 2026 | 31d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | +39.4%S&P 500 +9.8% · +29.6 pts vs S&P 500 | Jan 30, 2026 | Feb 13, 2026 | 14d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +42.3%S&P 500 +9.5% · +32.8 pts vs S&P 500 | Jan 29, 2026 | Feb 6, 2026 | 8d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +83.4%S&P 500 +17.8% · +65.6 pts vs S&P 500 | Aug 26, 2025 | Sep 9, 2025 | 14d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +93.7%After the saleS&P 500 +27.8% · +65.9 pts vs S&P 500 | May 19, 2025 | Jun 10, 2025 | 22d |
| Robert Bresnahan | Stock | Purchase | $1,001 - $15,000 | +102.7%S&P 500 +28.7% · +74.0 pts vs S&P 500 | May 15, 2025 | Jun 9, 2025 | 25d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +112.1%S&P 500 +42.0% · +70.2 pts vs S&P 500 | Apr 23, 2025 | May 12, 2025 | 19d |
| Robert Bresnahan | Stock | Sale | $1,001 - $15,000 | +119.8%After the saleS&P 500 +53.0% · +66.9 pts vs S&P 500 | Apr 8, 2025 | May 8, 2025 | 30d |
| Robert Bresnahan | Stock | Purchase | $1,001 - $15,000 | +74.8%S&P 500 +27.9% · +46.9 pts vs S&P 500 | Feb 25, 2025 | Mar 27, 2025 | 30d |
Since the trade is an estimate, set beside the S&P 500 over the same window, with the gap between the two in percentage points. The filing carries a band, not a fill, and a sale keeps the stock's sign, so a positive figure after a sale means the stock kept rising after it. An option row carries the underlying stock's move. A row marked n/a is one we hold no figure for.
A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.
"Not captured" means the band or the transaction type on the original report is missing from our data.
"Dates conflict" marks a row whose disclosure is dated before its trade on the record we hold. Both dates are printed as filed, and no since-the-trade figure is computed from them.
Every Congress trade in BIIB, filterable by party, chamber, type and account.
Members of Congress reporting a position
6 members · estimate, as of Oct 21, 20266 members report a position (estimated). The largest estimated position is in the $100,001 - $250,000 band.
| Member | Party, chamber | Estimated position | Share of their portfolio |
|---|---|---|---|
| J. French Hill | Republican · House | $100,001 - $250,000 | 0.6% |
| Maria Elvira Salazar | Republican · House | $50,001 - $100,000 | 2.8% |
| Lucy McBath | Democrat · House | $15,001 - $50,000 | 0.3% |
| Gilbert Ray Cisneros, Jr. | Democrat · House | $15,001 - $50,000 | 0.1% |
| Robert Bresnahan | Republican · House | $1,001 - $15,000 | 0.1% |
| Kevin Hern | Republican · House | $1,001 - $15,000 | <0.1% |
Estimate, as of Oct 21, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, moved with the stock's price since the trade. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.
Questions
Are insiders buying or selling BIIB?
Across the 4 most recent open-market filings shown here, 1 was a purchase and 3 were sales. 3 were scheduled in advance under a Rule 10b5-1 plan.
Which members of Congress have traded BIIB?
Maria Elvira Salazar, Kevin Hern, Alan Armstrong, Gilbert Ray Cisneros, Jr., Ro Khanna and Robert Bresnahan disclosed BIIB transactions in the filings shown here.
Which members of Congress hold BIIB?
6 members of Congress report a position in BIIB in the estimate we hold as of Oct 21, 2026. The two largest estimated positions belong to J. French Hill and Maria Elvira Salazar; Lucy McBath holds one of the next largest, in the $15,001 - $50,000 band. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.
Is BIIB in the S&P 500 or the Nasdaq 100?
Biogen Inc. is a current member of the S&P 500, per the membership list we hold as of Oct 26, 2026. Current members of either index get a page here whatever their filing history.
How quickly are BIIB trades disclosed?
Insider filings on this page reached the public a median of 2 business days after the transaction (weekends and federal holidays skipped), against the two business days Form 4 allows. Congressional disclosures took a median of 26 days, against the 45 the STOCK Act allows.
How to read a Form 4
A DECISION THE INSIDER MADE
COMPENSATION PLUMBING
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Oct 26, 2026.
